Chester County News and Community Website
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will release its first-quarter 2025 financial results on Thursday, May 1, 2025, before U.S. markets open.
Madrigal Pharmaceuticals to Announce Q1 2025 Results with Live Webcast Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced a key leadership transition as founder and Chief Medical Officer Dr. Rebecca Taub steps into the role of Senior Scientific …
Leadership Changes at Madrigal Pharmaceuticals Mark New Phase of Growth Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the appointment of Jacqualyn (“Jackie”) Fouse, Ph.D., to its Board of Directors, bringing decades of leadership and expertise in the biotech …
Madrigal Pharmaceuticals Announces Changes to Board of Directors Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced its financial results for 2024, marking a pivotal year highlighted by the FDA approval and successful launch of Rezdiffra (resmetirom). Rezdiffra, …
Madrigal Pharmaceuticals Reports Strong 2024 Growth Fueled by Rezdiffra Launch Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced positive two-year results from the Phase 3 MAESTRO-NAFLD-1 trial, demonstrating the potential of Rezdiffra (resmetirom) to significantly reduce liver stiffness in …
Madrigal Pharmaceuticals Reports Promising Two-Year Results for MASH Therapy Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced its participation in the 45th Annual TD Cowen Health Care Conference, scheduled to take place on Tuesday, March 4, 2025, …
Madrigal Pharmaceuticals to Present at 45th Annual TD Cowen Health Care Conference Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has released a business update highlighting strong preliminary financial results for 2024 and the ongoing success of its breakthrough treatment, Rezdiffra™ (resmetirom), …
Madrigal Reports Robust 2024 Performance and Plans for Growth Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has reported its financial and operational achievements for the third quarter of 2024, highlighting robust net sales and strategic progress with its …
Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has successfully completed enrollment for its MAESTRO-NASH OUTCOMES trial, a critical study evaluating the efficacy of resmetirom in patients with compensated NASH …
Madrigal Pharmaceuticals Advances NASH Treatment with Full Enrollment of MAESTRO-NASH OUTCOMES Trial Read More CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced the appointment of Dr. Michael R. Charlton as Senior Vice President of Clinical Development, effective October 1, 2024. This key addition …
Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as SVP of Clinical Development Read More